CB Therapeutics · Mar 2026
CB Therapeutics launched Korvane, a non-opioid pain research program focused on minor kratom alkaloids, with a mixed production route using yeast fermentation where possible and downstream chemistry where needed.
Fermentation-derived natural products to solve health problems
Public company, workplace, funding, and market signals
CB Therapeutics is a Carlsbad-based synthetic biology company using precision fermentation and engineered yeast to produce rare molecules for biotech, mental-health, non-opioid pain, healthspan, and food/nutrition applications.
Primary product
Engineered-yeast precision-fermentation platform for rare molecules (cannabinoids, tryptamines, alkaloids, peptides, terpenes, and designed analogs)
Founded
2015
Headquarters
Carlsbad, California, United States
Team size
11-50
Work style
Onsite
Industry
Biotechnology
Sub-industry
Precision fermentation / synthetic biology
Offices
0 jobs at CB Therapeutics
Check back later for new openings
Business model
Stage
Series A
Total raised
$11.6M
Latest round
Series A · May 2021
Leadership
CEO & Co-founder
CSO & Co-founder
Operations Executive
Erin Scott
Director of Microbiology
Laura Peiffer
Associate Director of Strain Engineering
Jim Wade
Director of Analytical Chemistry
Aaron Cantu
Head of Fermentation & Downstream
Investors
Small, bench-focused, multidisciplinary team; collaborative and research-driven, with heavy emphasis on iterative lab work, fermentation, analytics, and moving molecules from design to production.
Work style
Onsite
Compensation
No public salary bands were found. Third-party salary data suggests average pay around $102k/year with a typical range near $90k-$116k, but that appears to be an external estimate rather than company-published compensation.
Pricing
B2B partnership model: research collaboration, licensing, co-development, and custom supply of fermentation-derived compounds
Differentiators
Technology
Customers
Competitors
Estimated revenue
USD 0-1M on LinkedIn/company directories; other third-party directories estimate higher
Estimated monthly visits
1.4K
CB Therapeutics · Mar 2026
CB Therapeutics launched Korvane, a non-opioid pain research program focused on minor kratom alkaloids, with a mixed production route using yeast fermentation where possible and downstream chemistry where needed.
CB Therapeutics · Dec 2025
CB Therapeutics launched Aevora, a peptide-enriched yeasted-extract program aimed at healthspan, longevity, weight-loss, and hair-regrowth applications.
CB Therapeutics · Oct 2025
CB Therapeutics introduced TryptageniX AI, its data-and-ML layer for tightening strain design through a lab-to-model feedback loop.
AccessWire · Jan 2025
CB Therapeutics expanded its platform into ergoline-based compounds, emphasizing yeast-based precision fermentation for scalable, eco-conscious production of molecules relevant to neurology and psychiatry.
Newsfile · May 2024
CB Therapeutics announced precision-fermentation-based retinol production for skincare and clean-beauty applications, highlighting sustainability and collaboration opportunities.